PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another milestone under the CF101 development and marketing agreement signed with the Japanese company, and will receive a consideration of US$ 500,000. The Company announced today the completion of enrolment of 250 patients in its phase IIb RA trial. Completion of patient enrolment is one of the milestones set forth in the marketing agreement, which was recently signed with the Japanese Seikagaku Corporation, and by achieving this milestone Can-Fite will now receive US$ 500,000.
